Design and validation of specific inhibitors of 17 -hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
17beta-Hydroxysteroid dehydrogenases (17beta-HSDs) are enzymes that are responsible for reduction or oxidation of hormones, fatty acids and bile acids in vivo, regulating the amount of the active form that is available to bind to its cognate receptor. All require NAD(P)(H) for activity. Fifteen 17beta-HSDs have been identified to date, and with one exception, 17beta-HSD type 5 (17beta-HSD5), an aldo-keto reductase, they are all short-chain dehydrogenases/reductases, although overall homology between the enzymes is low. Although named as 17beta-HSDs, reflecting the major redox activity at the 17beta-position of the steroid, the activities of these 15 enzymes vary, with several of the 17beta-HSDs able to reduce and/or oxidise multiple substrates at various positions. These activities are involved in the progression of a number of diseases, including those related to steroid metabolism. Despite the success of inhibitors of steroidogenic enzymes in the clinic, such as those of aromatase and steroid sulphatase, the development of inhibitors of 17beta-HSDs is at a relatively early stage, as at present none have yet reached clinical trials. However, many groups are now working on inhibitors specific for several of these enzymes for the treatment of steroid-dependent diseases, including breast and prostate cancer, and endometriosis, with demonstrable efficacy in in vivo disease models. In this review, the recent advances in the validation of these enzymes as targets for the treatment of these diseases, with emphasis on 17beta-HSD1, 3 and 5, the development of specific inhibitors, the models used for their evaluation, and their progress towards the clinic will be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
Sampson, J. A. (1927) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(15)30003-x · Cited by 2,334
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
PENNING, T. M., BURCZYNSKI, M. E., JEZ, J. M., HUNG, C.-F., LIN, H.-K., MA, H., MOORE, M., PALACKAL, N., & RATNAM, K. (2000) · Biochemical Journal · doi:10.1042/bj3510067 · Cited by 649 · cited 3×
“It has additional 3a- and 20a-steroid reductase activities (Dufort et al. 1999, Penning et al. 2000), including the protective inactivation of deoxycorticosterone in mineralocorticoid tissues (Sharma et al. 2006).”
BackgroundMale pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3
Geissler, W. M., Davis, D. L., Wu, L., Bradshaw, K. D., Patel, S., Mendonca, B. B., Elliston, K. O., Wilson, J. D., Russell, D. W., & Andersson, S. (1994) · Nature Genetics · doi:10.1038/ng0594-34 · Cited by 570 · cited 3×
“A defect in the expression of 17b-HSD3 causes the autosomal recessive genetic disorder, male pseudohermaphroditism (Geissler et al. 1994), in which the individual is usually reared as a female, often having been born with female external genitalia and the 675 Downloaded from Bioscientifica.com at…”
BackgroundTestosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer
Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B., & Mohler, J. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0525 · Cited by 488 · cited 1×
“…in the prostates of patients with recurrence during ablation therapy, suggesting that surgical or chemical castration treatments may not result in complete removal of active androgens, and that in situ formation of testosterone from adrenal production of androgens may continue (Titus et al. 2005).”
BackgroundProgesterone resistance in endometriosis: link to failure to metabolize estradiol.
Bulun, S. E., Cheng, Y.-H., Yin, P., Imir, G., Utsunomiya, H., Attar, E., Innes, J., & Julie Kim, J. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.11.041 · Cited by 397
Du Yan, S., Fu, J., Soto, C., Chen, X., Zhu, H., Al-Mohanna, F., Collison, K., Zhu, A., Stern, E., Saido, T., et al. (1997) · Nature · doi:10.1038/39522 · Cited by 379 · cited 1×
“It has been implicated in the development of Alzheimer’s disease as it is overexpressed in neurones of patients with the disease, and associates with the neurotoxic peptide amyloid-b (Yan et al. 1997).”
BackgroundPeltoketo, H., Luu-The, V, Simard, J., & Adamski, J. (1999) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0230001 · Cited by 302 · cited 2×
“In female rodents, the major expression of 17b-HSD1 is in the ovary (Peltoketo et al. 1999), with low levels in the uterus and some expression in the sebaceous glands of the skin (Nokelainen et al. 1996, Pelletier et al. 2004).”
BackgroundLuu-The, V., Zhang, Y., Poirier, D., & Labrie, F. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00209-x · Cited by 224
Cited by
Marchais-Oberwinkler, S., Henn, C., Möller, G., Klein, T., Negri, M., Oster, A., Spadaro, A., Werth, R., Wetzel, M., Xu, K., et al. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.12.013 · Cited by 216
Estrogen metabolism and action in endometriosis
Rižner, T. L. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.03.022 · Cited by 153
Smeets, E. E. J. W., Span, P. N., van Herwaarden, A. E., Wevers, R. A., Hermus, A. R. M. M., Sweep, F. C. G. J., & Claahsen-van der Grinten, H. L. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2036 · Cited by 70
Delvoux, B., D'Hooghe, T., Kyama, C., Koskimies, P., Hermans, R. J. J., Dunselman, G. A., & Romano, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2851 · Cited by 59
Steroid sulfatase inhibitors: promising new tools for breast cancer therapy?
Geisler, J., Sasano, H., Chen, S., & Purohit, A. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.02.002 · Cited by 55
Self-citation
Metadata
- Authors
- Day, J. M., Tutill, H. J., Purohit, A., & Reed, M. J.
- Venue
- Endocrine Related Cancer
- Publisher
- Bioscientifica
- Published
- 2008-05-22
- Volume
- 15
- Issue
- 3
- Pages
- 665-692
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2097678737
- Cited by
- 122
- References
- 26
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Design and validation of specific inhibitors of 17 -hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. https://app.cochat.ai/papers/10.1677/erc-08-0042
- The paper
- Day, J. M., Tutill, H. J., Purohit, A., & Reed, M. J. (2008). Design and validation of specific inhibitors of 17 -hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocrine Related Cancer. https://doi.org/10.1677/erc-08-0042
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.